Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,548.00
Ask: 12,550.00
Change: 6.00 (0.05%)
Spread: 2.00 (0.016%)
Open: 12,570.00
High: 12,704.00
Low: 12,472.00
Prev. Close: 12,550.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-Shares rally, retail surge drives silver to 8-year high

Mon, 01st Feb 2021 10:08

* Global stocks up 0.5%; S&P 500 futures up 1%

* Retail crowd turns gaze on silver, jumps to 8-year high

* Oil up 1%; Dollar index, Bund, T-bill yields steady

* Excess Money? https://tmsnrt.rs/2YpThUB

By Simon Jessop

LONDON, Feb 1 (Reuters) - Global shares bounced and silver
markets surged on Monday as retail investors expanded their
social-media fuelled battle against Wall Street to drive the
precious metal to an eight-year high.

Stock markets were roiled last week after a spike in retail
demand to buy the stocks most bet against by hedge funds drove
huge gains in companies such as GameStop Corp and
prompted fresh concern that COVID-19 monetary and fiscal support
measures were fuelling a market bubble.

With chatrooms abuzz with talk that silver was the new
target, silver-exposed stocks, funds and coins jumped, helping
push spot silver up more than 11%, with London-listed
miners up strongly, including Fresnillo, up 18%.

After falling 3.6% last week - its biggest weekly fall in
three months - the MSCI All-Country World Index
was up 0.5% in early deals, tracking overnight gains in Asia.

MSCI's broadest index of Asia-Pacific shares outside Japan
climbed 1.9% while Japan's Nikkei added
1.5% and Chinese blue chips rose 1.2% after the
country's central bank injected more cash into money markets.

Futures for the S&P 500 and NASDAQ, meanwhile,
both pointed to a stronger open on Wall Street, up around 1%.

While the retail battle versus Wall Street, coordinated over
online forums such as Reddit, created some systemic risks, the
bigger danger was in the tech sector, where some stocks had "eye
watering valuations", Deutsche Bank analyst Jim Reid said.

"Retail has in many parts driven such valuations in the last
10 months. If this pops the wider market will have bigger issues
than last week."

Gold followed silver higher, up 1% to $1,864 an ounce
, while oil also tracked the gains in other commodities,
with both Brent crude and its U.S. peer up around
1%.

While the stock market tussle continued to grab the
headlines, analysts cautioned the bigger concern was economic
momentum in the United States and Europe as coronavirus
lockdowns bite.

Indeed, two surveys from China showed factory activity
slowed in January as restrictions took a toll in some regions.
In the euro zone, manufacturing growth remained resilient at the
start of the year but the pace waned from December. Data from
Britain will be in focus later in the European session.

While the coronavirus vaccine rollout globally remains slow,
with concern about whether they will work on new COVID strains,
Europe was also bolstered by news that it would receive a
further 9 million doses from AstraZeneca in the first quarter.

"It is these considerations, not what is happening to a
video game retailer day to day, that has weighed on risk
assets," said John Briggs, global head of strategy at NatWest
Markets. "So much of the market's valuations, risk in
particular, is premised on the fact we can see a light at the
end of the COVID tunnel."

Higher yields combined with the more cautious market mood
have seen the safe-haven dollar steady above its recent lows.
The dollar index stood at 90.722, having bounced from a
trough of 89.206 hit early in January.

The euro, meanwhile, fell 0.3% to $1.2100, well off
its recent peak at $1.2349, while the pound was the biggest
gainer in the G10 group of currencies, up 0.3% on the day at
$1.3732..

With riskier markets bouncing, Italian government bond
yields fell 2-3 basis points across the curve.

German Bund yields, meanwhile, the benchmark for the euro
zone, remained anchored around -0.51% on Monday, tracking U.S.
Treasury yields that also remained unchanged..

(Additional reporting by Abhinav Ramnarayan and Ritvik
Carvalho; Editing by Toby Chopra, William Maclean)

More News
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more
9 Nov 2023 09:23

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

Read more
9 Nov 2023 08:57

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

Read more
9 Nov 2023 07:48

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

Read more
9 Nov 2023 07:18

AstraZeneca hikes guidance after strong third quarter

(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.

Read more
3 Nov 2023 17:06

AstraZeneca plans next phase of trial on kidney drug combination data

(Alliance News) - AstraZeneca PLC on Friday touted results from a Phase IIb trial, which showed that a zibotentan and dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.